Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells

Seohyun Lee, Mak Soon Lee, Chong Tai Kim, In-Hwan Kim, Yangha Kim

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is one of the main causes of mortality worldwide, and dyslipidemia is a major risk factor for CVD. Ginseng has been widely used in the clinic to treat CVD. Ginsenoside Rg3, one of the major active components of ginseng, has been reported to exhibit antiobesity, antidiabetic, and cardioprotective effects. However, the effect of ginsenoside Rg3 on hepatic lipid metabolism remains unclear. Therefore, we investigated whether ginsenoside Rg3 would regulate hepatic lipid metabolism with AMP-activated protein kinase (AMPK) activation in HepG2 cells. Ginsenoside Rg3 significantly reduced hepatic cholesterol and triglyceride levels. Furthermore, ginsenoside Rg3 inhibited expression of sterol regulatory element binding protein-2 (SREBP-2) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Ginsenoside Rg3 increased activity of AMPK, a major regulator of energy metabolism. These results suggest that ginsenoside Rg3 reduces hepatic lipid accumulation with inhibition of SREBP-2 and HMGCR expression and stimulation of AMPK activity in HepG2 cells. Therefore, ginsenoside Rg3 may be beneficial as a food ingredient to lower the risk of CVD by regulating dyslipidemia.

Original languageEnglish
Pages (from-to)5729-5739
Number of pages11
JournalInternational Journal of Molecular Sciences
Volume13
Issue number5
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

adenosine monophosphate
Ginsenosides
AMP-Activated Protein Kinases
Hep G2 Cells
Lipids
lipids
Chemical activation
activation
Coenzymes
proteins
Proteins
lipid metabolism
coenzymes
cells
Sterol Regulatory Element Binding Protein 2
Cardiovascular Diseases
Enzyme inhibition
Panax
Liver
Cholesterol

Keywords

  • AMPK
  • Cardiovascular disease (CVD)
  • Cholesterol
  • Ginsenoside Rg3
  • HMGCR
  • SREBP-2
  • Triglyceride

ASJC Scopus subject areas

  • Computer Science Applications
  • Molecular Biology
  • Catalysis
  • Inorganic Chemistry
  • Spectroscopy
  • Organic Chemistry
  • Physical and Theoretical Chemistry

Cite this

Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells. / Lee, Seohyun; Lee, Mak Soon; Kim, Chong Tai; Kim, In-Hwan; Kim, Yangha.

In: International Journal of Molecular Sciences, Vol. 13, No. 5, 01.05.2012, p. 5729-5739.

Research output: Contribution to journalArticle

@article{d072a8c2f84b41b58a1c5cc6d2b7db81,
title = "Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells",
abstract = "Cardiovascular disease (CVD) is one of the main causes of mortality worldwide, and dyslipidemia is a major risk factor for CVD. Ginseng has been widely used in the clinic to treat CVD. Ginsenoside Rg3, one of the major active components of ginseng, has been reported to exhibit antiobesity, antidiabetic, and cardioprotective effects. However, the effect of ginsenoside Rg3 on hepatic lipid metabolism remains unclear. Therefore, we investigated whether ginsenoside Rg3 would regulate hepatic lipid metabolism with AMP-activated protein kinase (AMPK) activation in HepG2 cells. Ginsenoside Rg3 significantly reduced hepatic cholesterol and triglyceride levels. Furthermore, ginsenoside Rg3 inhibited expression of sterol regulatory element binding protein-2 (SREBP-2) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Ginsenoside Rg3 increased activity of AMPK, a major regulator of energy metabolism. These results suggest that ginsenoside Rg3 reduces hepatic lipid accumulation with inhibition of SREBP-2 and HMGCR expression and stimulation of AMPK activity in HepG2 cells. Therefore, ginsenoside Rg3 may be beneficial as a food ingredient to lower the risk of CVD by regulating dyslipidemia.",
keywords = "AMPK, Cardiovascular disease (CVD), Cholesterol, Ginsenoside Rg3, HMGCR, SREBP-2, Triglyceride",
author = "Seohyun Lee and Lee, {Mak Soon} and Kim, {Chong Tai} and In-Hwan Kim and Yangha Kim",
year = "2012",
month = "5",
day = "1",
doi = "10.3390/ijms13055729",
language = "English",
volume = "13",
pages = "5729--5739",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells

AU - Lee, Seohyun

AU - Lee, Mak Soon

AU - Kim, Chong Tai

AU - Kim, In-Hwan

AU - Kim, Yangha

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Cardiovascular disease (CVD) is one of the main causes of mortality worldwide, and dyslipidemia is a major risk factor for CVD. Ginseng has been widely used in the clinic to treat CVD. Ginsenoside Rg3, one of the major active components of ginseng, has been reported to exhibit antiobesity, antidiabetic, and cardioprotective effects. However, the effect of ginsenoside Rg3 on hepatic lipid metabolism remains unclear. Therefore, we investigated whether ginsenoside Rg3 would regulate hepatic lipid metabolism with AMP-activated protein kinase (AMPK) activation in HepG2 cells. Ginsenoside Rg3 significantly reduced hepatic cholesterol and triglyceride levels. Furthermore, ginsenoside Rg3 inhibited expression of sterol regulatory element binding protein-2 (SREBP-2) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Ginsenoside Rg3 increased activity of AMPK, a major regulator of energy metabolism. These results suggest that ginsenoside Rg3 reduces hepatic lipid accumulation with inhibition of SREBP-2 and HMGCR expression and stimulation of AMPK activity in HepG2 cells. Therefore, ginsenoside Rg3 may be beneficial as a food ingredient to lower the risk of CVD by regulating dyslipidemia.

AB - Cardiovascular disease (CVD) is one of the main causes of mortality worldwide, and dyslipidemia is a major risk factor for CVD. Ginseng has been widely used in the clinic to treat CVD. Ginsenoside Rg3, one of the major active components of ginseng, has been reported to exhibit antiobesity, antidiabetic, and cardioprotective effects. However, the effect of ginsenoside Rg3 on hepatic lipid metabolism remains unclear. Therefore, we investigated whether ginsenoside Rg3 would regulate hepatic lipid metabolism with AMP-activated protein kinase (AMPK) activation in HepG2 cells. Ginsenoside Rg3 significantly reduced hepatic cholesterol and triglyceride levels. Furthermore, ginsenoside Rg3 inhibited expression of sterol regulatory element binding protein-2 (SREBP-2) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Ginsenoside Rg3 increased activity of AMPK, a major regulator of energy metabolism. These results suggest that ginsenoside Rg3 reduces hepatic lipid accumulation with inhibition of SREBP-2 and HMGCR expression and stimulation of AMPK activity in HepG2 cells. Therefore, ginsenoside Rg3 may be beneficial as a food ingredient to lower the risk of CVD by regulating dyslipidemia.

KW - AMPK

KW - Cardiovascular disease (CVD)

KW - Cholesterol

KW - Ginsenoside Rg3

KW - HMGCR

KW - SREBP-2

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=84861548814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861548814&partnerID=8YFLogxK

U2 - 10.3390/ijms13055729

DO - 10.3390/ijms13055729

M3 - Article

C2 - 22754327

AN - SCOPUS:84861548814

VL - 13

SP - 5729

EP - 5739

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 5

ER -